يحاول ذهب - حر
Prosus eyes biggest bite of Swiggy’s Rapido stake
September 16, 2025
|Mint Mumbai
Deal may value Rapido at up to $2.7 bn; Nexus, WestBridge too want to raise stakes
Dutch technology investor Prosus NV is looking to snap up the largest piece of Swiggy’s stake in Rapido, three people familiar with the matter said, in a deal that could value the ride-hailing startup at as much as $2.7 billion.
Prosus is looking to invest $150-180 million for a significant portion of the roughly 12% stake that Swiggy holds in Rapido, one of the three people said on the condition of anonymity. Meanwhile, Rapido’s existing investors Nexus Venture Partners and WestBridge Capital are also seeking to increase their holdings.
Rapido was last valued at $1.1 billion in September 2024, when it secured $200 million in its Series E fundraising round led by West-Bridge Capital. If Swiggy sale indeed values Rapido at $2.7 billion, the 12% stake would be worth a little over $320 million, or 2,825 crore.
Swiggy, which had acquired the Rapido stake in April 2022 for $180 million, informed shareholders in July that it would reevaluate the investment after the mobility startup decided to enter Swiggy’s stronghold of food delivery.
As of June, Prosus owned about 2.7% in Rapido, while Nexus and WestBridge owned 9.9% and 19%, respectively, show data accessed by Tracxn. Rapido founders Pavan Guntupalli and Aravind Sanka own 4.8% each, while Rishikesh S.R., another co-founder, owns 1.8%.
هذه القصة من طبعة September 16, 2025 من Mint Mumbai.
اشترك في Magzter GOLD للوصول إلى آلاف القصص المتميزة المنسقة، وأكثر من 9000 مجلة وصحيفة.
هل أنت مشترك بالفعل؟ تسجيل الدخول
المزيد من القصص من Mint Mumbai
Mint Mumbai
Gen Alpha will make new rules for their workplace
Gen Alpha will expect hybrid workplaces, Al tools and 4-day weeks— offices unrecognizable to their parents’
3 mins
December 01, 2025
Mint Mumbai
EC extends electoral roll revision by a week to II Dec; final list on 14 Feb
The Election Commission on Sunday extended by one week the entire schedule of the ongoing special intensive revision (SIR) of electoral rolls in nine states and three Union territories amid allegations by opposition parties that the “tight timelines” were creating problems for people and ground-level poll officials.
2 mins
December 01, 2025
Mint Mumbai
THE PROBLEM IS NOT JUST ABOUT DYNASTIC POLITICS
These days Tejashvi Yadav is the target of intense trolling. Before him the Huda family in Haryana and Thackerays in Maharashtra got the same treatment. So, is the battle of victory and defeat in electoral politics a tussle between dynasts vs the rest? Absolutely not.
3 mins
December 01, 2025
Mint Mumbai
Green hydrogen: Fast fashion could help bump up demand
A boom in its use for clean synthetic inputs might make a difference
3 mins
December 01, 2025
Mint Mumbai
Let's be a bit more selective in using the word 'reforms'
Everybody should take a beat and think before uttering the word ‘reforms’ the next time. Glib usage, frequently in the wrong context, threatens to rob the word of its import.
3 mins
December 01, 2025
Mint Mumbai
As mid-cap alpha shrinks, should you consider passive strategies?
Advisers urge a balanced mix—add passives slowly and back strong, active managers, as mid-caps are still pricey
4 mins
December 01, 2025
Mint Mumbai
With $2.2 bn fund, ChrysCap has appetite for riskier bets
MD Saurabh Chatterjee details shift in global LP base, renewed focus on manufacturing
3 mins
December 01, 2025
Mint Mumbai
GDP growth of 8% plus: How to sustain this pace
Last quarter's economic expansion has cheered India but the challenge is to sustain a brisk rate for years to come. For private investment to chip in, revive infrastructure partnerships
2 mins
December 01, 2025
Mint Mumbai
INSIDE INDIA'S ATTEMPT TO TAME DEEPFAKES
Detection tools today are not universal or consistent across languages
5 mins
December 01, 2025
Mint Mumbai
APIs to innovation: Bulk drug makers ramp up CDMO bets
Once focused on low-margin active pharmaceutical ingredients (APIs), India’s bulk drug manufacturers are raising their ambitions, with several now investing heavily in research and development to win contract development and manufacturing work from global drugmakers.
2 mins
December 01, 2025
Listen
Translate
Change font size

